{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:22:03Z","timestamp":1768828923363,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870140"],"award-info":[{"award-number":["81870140"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670166"],"award-info":[{"award-number":["81670166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81530046"],"award-info":[{"award-number":["81530046"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81873445"],"award-info":[{"award-number":["81873445"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s00277-020-04003-8","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T05:20:08Z","timestamp":1585027208000},"page":"2649-2657","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A retrospective analysis on anti-CD20 antibody\u2013treated Epstein\u2013Barr virus\u2013related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation"],"prefix":"10.1007","volume":"99","author":[{"given":"Xue-Yi","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Jun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"issue":"56","key":"4003_CR1","doi-asserted-by":"publisher","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","volume":"2","author":"VR Dharnidharka","year":"2016","unstructured":"Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S (2016) Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers 2(56):15088","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"4003_CR2","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.bbmt.2013.07.013","volume":"19","author":"JA Kanakry","year":"2013","unstructured":"Kanakry JA, Kasamon YL, Bola\u00f1os-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, Ghosh N, Gladstone DE, Gocke CD, Huff CA (2013) Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 19(10):1514\u20131517","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"4003_CR3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/bmt.2013.190","volume":"49","author":"J Sanz","year":"2014","unstructured":"Sanz J, Arango M, Senent L, Jarque I, Montesinos P, Sempere A, Lorenzo I, Mart\u00edn G, Moscard\u00f3 F, Mayordomo E (2014) EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant 49(3):397\u2013402","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"4003_CR4","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1200\/JCO.2003.05.108","volume":"21","author":"KS Baker","year":"2003","unstructured":"Baker KS, Defor TE, Burns LJ, Ramsay NKC, Neglia JP, Robison LL (2003) New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. Jclinoncol 21(7):1352","journal-title":"Jclinoncol"},{"issue":"2","key":"4003_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2013.087338","volume":"99","author":"U Michael","year":"2014","unstructured":"Michael U, Helena W, Mikael S, Ola B, Markus M, Olle R, Jacek W, Per L, Mats R, Jonas M (2014) Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 99(2):346\u2013352","journal-title":"Haematologica"},{"issue":"2","key":"4003_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/bmt.2013.170","volume":"49","author":"CP Fox","year":"2014","unstructured":"Fox CP, Burns D, Parker AN, Peggs KS, Harvey CM, Natarajan S, Marks DI, Jackson B, Chakupurakal G, Dennis M (2014) EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant 49(2):280\u2013286","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"4003_CR7","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1182\/blood-2006-03-011791","volume":"108","author":"CG Brunstein","year":"2006","unstructured":"Brunstein CG, Weisdorf DJ, Defor T, Barker JN, Tolar J, Burik JAHV, Wagner JE (2006) Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108(8):2874\u20132880","journal-title":"Blood"},{"issue":"6","key":"4003_CR8","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1182\/blood-2006-12-062174","volume":"110","author":"JM Cohen","year":"2007","unstructured":"Cohen JM, Sebire NJ, Harvey J, Gaspar HB, Cathy C, Jones A, Rao K, Cubitt D, Amrolia PJ, Davies EG (2007) Successful treatment of lymphoproliferative disease complicating primary immunodeficiency\/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation. Blood 110(6):2209\u20132214","journal-title":"Blood"},{"issue":"11","key":"4003_CR9","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00432-014-1742-z","volume":"140","author":"A Mensen","year":"2014","unstructured":"Mensen A, Na IK, H\u00e4fer R, Meerbach A, Schlecht M, Pietschmann ML, Gruhn B (2014) Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD. J Cancer Res Clin Oncol 140(11):1971\u20131980","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"4003_CR10","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1182\/blood-2006-03-011791","volume":"108","author":"CG Brunstein","year":"2015","unstructured":"Brunstein CG, Weisdorf DJ, Defor T, Barker JN, Tolar J, van Burik JA, Wagner JE (2015) Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108(8):2874\u20132880","journal-title":"Blood"},{"issue":"2","key":"4003_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2013.087338","volume":"99","author":"M Uhlin","year":"2014","unstructured":"Uhlin M, Wikell H, Sundin M, Blennow O, Maeurer M, Ringden O, Winiarski J, Ljungman P, Remberger M, Mattsson J (2014) Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 99(2):346\u2013352","journal-title":"Haematologica"},{"issue":"12","key":"4003_CR12","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.bbmt.2015.07.035","volume":"21","author":"LP Xu","year":"2015","unstructured":"Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, Chen YH, Wang Y, Yan CH, Wang JZ (2015) Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant 21(12):2185\u20132191","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"4003_CR13","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","volume":"126","author":"D Dierickx","year":"2015","unstructured":"Dierickx D, Tousseyn T, Gheysens O (2015) How I treat posttransplant lymphoproliferative disorders. Blood 126(20):2274\u20132283","journal-title":"Blood"},{"issue":"7","key":"4003_CR14","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","volume":"101","author":"J Styczynski","year":"2016","unstructured":"Styczynski J, Velden WVD, Fox CP, Dan E, Camara RDL, Cordonnier C, Ljungman P (2016) Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 101(7):803\u2013811","journal-title":"Haematologica"},{"issue":"2","key":"4003_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/bmt.2013.96","volume":"49","author":"L Rasche","year":"2013","unstructured":"Rasche L, Kapp M, Einsele H, Mielke S (2013) EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant 49(2):163\u2013167","journal-title":"Bone Marrow Transplant"},{"key":"4003_CR16","doi-asserted-by":"publisher","unstructured":"Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S (2013) Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis 57(6):794\u2013802. doi: https:\/\/doi.org\/10.1093\/cid\/cit391","DOI":"10.1093\/cid\/cit391"},{"issue":"3","key":"4003_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/tid.12061","volume":"15","author":"F Patriarca","year":"2013","unstructured":"Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, Toffoletti E, Dozzo M, Michelutti A, Gregoraci G (2013) Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl Infect Dis 15(3):259\u2013267","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"4003_CR18","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/bmt.2013.84","volume":"48","author":"VDV Wj","year":"2013","unstructured":"Wj VDV, Mori T, Stevens WB, de Haan AF, Stelma FF, Blijlevens NM, Donnelly JP (2013) Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. Bone Marrow Transplant 48(11):1465\u20131471","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"4003_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/bmt.2014.298","volume":"50","author":"I Garc\u00edacadenas","year":"2015","unstructured":"Garc\u00edacadenas I, Castillo N, Martino R, Barba P, Esquirol A, Novelli S, Orti G, Garrido A, Saavedra S, Moreno C (2015) Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. Bone Marrow Transplant 50(4):579\u2013584","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"4003_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1179\/1607845413Y.0000000123","volume":"19","author":"SC Meyer","year":"2014","unstructured":"Meyer SC, Medinger M, Halter JP, Baldomero H, Hirsch HH, Tzankov A, Dirnhofer S, Passweg JR, Tichelli A (2014) Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation. Hematology 19(5):280\u2013285","journal-title":"Hematology"},{"issue":"5","key":"4003_CR21","doi-asserted-by":"publisher","first-page":"e1139274","DOI":"10.1080\/2162402X.2016.1139274","volume":"5","author":"X Jiang","year":"2016","unstructured":"Jiang X, Xu L, Zhang Y, Huang F, Liu D, Sun J, Song C, Liang X, Fan Z, Zhou H, Dai M, Liu C, Jiang Q, Xu N, Xuan L, Wu M, Huang X, Liu Q (2016) Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation. Oncoimmunology 5(5):e1139274. https:\/\/doi.org\/10.1080\/2162402X.2016.1139274","journal-title":"Oncoimmunology"},{"issue":"8","key":"4003_CR22","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1182\/blood-2005-05-2146","volume":"107","author":"DP Lu","year":"2006","unstructured":"Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH (2006) Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 107(8):3065\u20133073","journal-title":"Blood"},{"issue":"6","key":"4003_CR23","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15(6):825\u2013828","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"4003_CR24","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2015","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D (2015) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945\u2013956","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"4003_CR25","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1158\/1078-0432.CCR-09-0691","volume":"15","author":"H Xiao-Jun","year":"2009","unstructured":"Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C, Yu-Hong C, Wei H, Jing-Zhi W, Yao C (2009) Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 15(14):4777\u20134783","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4003_CR26","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1097\/TP.0b013e3181dd6c0a","volume":"89","author":"S Cesaro","year":"2010","unstructured":"Cesaro S, Pegoraro A, Tridello G, Calore E, Pillon M, Varotto S, Abate D, Barzon L, Mengoli C, Carli M (2010) A prospective study on modulation of immunosuppression for Epstein-Barr virus reactivation in pediatric patients who underwent unrelated hematopoietic stem-cell transplantation. Transplantation 89(12):1533\u20131540","journal-title":"Transplantation"},{"key":"4003_CR27","doi-asserted-by":"publisher","unstructured":"Kobayashi S, Sano H, Mochizuki K, Ohara Y, Takahashi N, Ohto H, Kikuta A (2017) Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation. Pediatr Int 59(9):973\u2013978. https:\/\/doi.org\/10.1111\/ped.13336","DOI":"10.1111\/ped.13336"},{"issue":"7","key":"4003_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/ajh.23452","volume":"88","author":"Q Liu","year":"2013","unstructured":"Liu Q, Xuan L, Liu H, Huang F, Zhou H, Fan Z, Zhao K, Wu M, Xu L, Zhai X (2013) Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol 88(7):550\u2013555","journal-title":"Am J Hematol"},{"issue":"5","key":"4003_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood.V97.5.1165","volume":"97","author":"SJ Stevens","year":"2001","unstructured":"Stevens SJ, Verschuuren EA, Pronk I, Van DBW, Harmsen MC, The TH, Meijer CJ, Aj VDB, Middeldorp JM (2001) Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 97(5):1165\u20131171","journal-title":"Blood"},{"issue":"8","key":"4003_CR30","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/TP.0b013e31819f1c49","volume":"87","author":"I Ahmad","year":"2009","unstructured":"Ahmad I, Cau NJ, Maaroufi Y, Meuleman N, Aoun M, Lewalle P, Martiat P, Crokaert F, Bron D (2009) Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 87(8):1240\u20131245","journal-title":"Transplantation"},{"issue":"5","key":"4003_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1399-3062.2009.00410.x","volume":"11","author":"H Omar","year":"2010","unstructured":"Omar H, H\u00e4gglund H, Gustafsson-Jernberg A, Leblanc K, Mattsson J, Remberger M, Ringd\u00e9n O, Sparrelid E, Sundin M, Winiarski J (2010) Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis 11(5):393\u2013399","journal-title":"Transpl Infect Dis"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04003-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-020-04003-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04003-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:20:08Z","timestamp":1616545208000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-020-04003-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["4003"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04003-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"1 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study protocol was approved by the ethics committee of Peking University People\u2019s Hospital. Informed consent was obtained in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}